MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Pfizer Book Value 2011-2025 | PFE
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Pfizer
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88.5 B | 89.3 B | 95.9 B | 77.5 B | 63.5 B | 63.4 B | 63.8 B | 71.7 B | 59.8 B | 65 B | 71.6 B | 76.6 B | 81.7 B | 82.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.9 B | 59.8 B | 75.1 B |
Quarterly Book Value Pfizer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93.1 B | 89 B | 90.6 B | 92.6 B | 88 B | 92.6 B | 97.2 B | 99.3 B | 101 B | 95.9 B | 92.9 B | 87.5 B | 82.7 B | 77.5 B | 76 B | 70.3 B | 68.9 B | 63.5 B | 63.5 B | 63.5 B | 63.5 B | 63.4 B | 63.4 B | 63.4 B | 63.4 B | 63.8 B | 63.8 B | 63.8 B | 63.8 B | 71.7 B | 71.7 B | 71.7 B | 71.7 B | 59.8 B | 59.8 B | 59.8 B | 59.8 B | 65 B | 65 B | 65 B | 65 B | 71.6 B | 71.6 B | 71.6 B | 71.6 B | 76.6 B | 76.6 B | 76.6 B | 76.6 B | 81.7 B | 81.7 B | 81.7 B | 81.7 B | 82.6 B | 82.6 B | 82.6 B | 82.6 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 B | 59.8 B | 75.3 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
-191 M | $ 17.91 | -1.0 % | $ 7.59 B |  Niderland |
 |
InflaRx N.V.
IFRX
|
61.4 M | $ 1.09 | -4.82 % | $ 152 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B |  USA |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
11.8 M | $ 1.15 | -1.71 % | $ 6.27 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
156 M | $ 3.03 | -0.49 % | $ 234 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-106 M | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
4.76 M | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Avenue Therapeutics
ATXI
|
1.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.66 | -1.49 % | $ 424 M | Britain |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
19 M | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
20.1 M | - | -9.72 % | $ 5.89 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
19.4 B | $ 94.72 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | USA |
 |
Zai Lab Limited
ZLAB
|
841 M | $ 18.4 | -0.97 % | $ 18.2 B | China |
 |
Catalyst Biosciences
CBIO
|
78.5 M | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
40.9 B | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
46.1 M | - | -0.88 % | $ 598 M | USA |
 |
Certara
CERT
|
1.06 B | $ 8.9 | -0.17 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |